Moclobemide
规格
71320-77-9CAS 号
636-108-5EC 号
4-chloro-N-(2-morpholin-4-ylethyl)benzamideIUPAC 名称
C13H17ClN2O2化学式
268.74 g/mol分子量
moclobemide; 71320-77-9; Aurorix; Moclobemid; Manerix; Moclobemida; Moclobemidum; Moclamine; p-Chloro-N-(2-morpholinoethyl)benzamide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide; GNF-PF-695; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; Ro 11-1163/000; Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-; DTXSID9040554; Ro-11-1163; PJ0Y7AZB63; BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-; Ro-11-1163/000; Ro-111163000; Moclobamide; DTXCID7020554; CHEBI:83531; Aurorex; NovoMoclobemide; NuMoclobemide; Apo Moclobemide; Nu Moclobemide; Moclobemid Puren; Novo Moclobemide; PMS Moclobemide; AZU, Moclobemid; Stada, Moclobemid; Moclobemide, DBL; von ct, Moclobemid; Moclobemide, GenRX; Moclobemid ratiopharm; Moclobemid1A Pharma; Moclobemid 1A Pharma; Moclobemide, Chem mart; 4-chloro-N-(2-(morpholin-4-yl)ethyl)benzamide; Moclobemide, Healthsense; Ro 11 1163; RefChem:389127; N06AG02; 4-chloro-N-(2-morpholinoethyl)benzamide; Moclaime; Moclamide; Moclobemidum [INN-Latin]; Moclobemida [INN-Spanish]; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; Ro 11-1163; Moclobemide (Ro 111163); MFCD00865388; Ro111163; CHEMBL86304; MLS000070549; NCGC00027930-02; NCGC00027930-04; SMR000012114; Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Auromid; Aurorix (TN); CAS-71320-77-9; HSDB 7180; SR-01000357772; CBMicro_048319; Moclobemide (USAN/INN); UNII-PJ0Y7AZB63; BRN 0530974; Moclobemide?; Moclamine (Salt/Mix); Moclobemide (Standard); Opera_ID_225; MOCLOBEMIDE [MI]; MOCLOBEMIDE [INN]; MOCLOBEMIDE [HSDB]; MOCLOBEMIDE [USAN]; MOCLOBEMIDE [MART.]; Oprea1_256739; Oprea1_270122; SCHEMBL49708; MOCLOBEMIDE [WHO-DD]; MLS000759438; MLS001240195; MLS001424077; GTPL7428; orb1224169; orb1310956; orb3141333; BENZAMIDE,4-CHLORO-N-[2-(4-MORPHOLINYL)ETHYL]-; Moclobemide - Bio-X trade mark; BDBM15613; HY-B0534R; GLXC-06724; HMS2051A16; HMS2096G07; HMS2232B20; HMS3262F09; HMS3371A01; HMS3393A16; HMS3657K05; HMS3713G07; HMS3885A15; HMS5081J08; HMS6018E20; HY-B0534; Moclobemide 1.0 mg/ml in Methanol; MSK11178; Tox21_110971; Tox21_113614; Tox21_500824; EBC-06887; HB1791; s3212; AKOS003270184; Moclobemide, >=98% (HPLC), solid; Tox21_110971_1; CCG-100879; DB01171; FM26030; LP00824; NC00129; SDCCGSBI-0048213.P003; NCGC00027930-03; NCGC00027930-05; NCGC00027930-07; NCGC00027930-09; NCGC00027930-16; NCGC00261509-01; AC-12467; AC-35244; BM164599; p-chloro-N-(2-morpholinoethyl)-benzamide; BIM-0048213.P001; M2733; M5610; NS00009131; ST45245423; SW197509-3; D02561; EN300-761488; 4-Chloro-N-[2-(4-morpholinyl)ethyl] benzamide; AB00400932_12; F801702; Q421934; SR-01000357772-1; SR-01000357772-4; BRD-K07237224-001-19-6; Z32409934; (4-chlorophenyl)-N-(2-morpholin-4-ylethyl)carboxamide; 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide; Aurorix; Moclamine; Ro-11-1163, Aurorix, Manerix, Moclamine, p-Chloro-N-(2-morpholinoethyl)benzamide; 108375-13-9同义词
